Summary of Key Takeaways:
- New regulations effective July 1, 2026, require traditional Chinese medicine (TCM) products to disclose adverse effects, contraindications, and precautions, ending the era of “尚不明确” (not yet clear) labels and initiating a widespread TCM product elimination.
- Over 70% of existing TCM product approvals face non-renewal, forcing manufacturers to invest in post-market safety studies or exit the market, with estimates suggesting 30-40% of approvals will be phased out.
- Small and medium enterprises (SMEs) bear the heaviest financial burden, with compliance costs potentially wiping out profits, while large, resource-rich firms are poised to gain market share from this consolidation.
- The policy aims to upgrade industry quality by eliminating “zombie approvals” and low-value products, aligning TCM with evidence-based standards to enhance global competitiveness and patient safety.
- Investors should monitor companies with strong R&D capabilities and proactive label revisions, as this TCM product elimination reshapes investment landscapes in Chinese pharmaceutical equities.
The traditional Chinese medicine (TCM) sector in China is bracing for its most significant regulatory upheaval in decades. A deadline set for July 1, 2026, mandates that all TCM products must have explicitly documented safety information on their labels, discarding vague terms like “尚不明确” (not yet clear). This move, widely referred to as the “生死条款” (life-and-death clause), is set to unleash a massive TCM product elimination, compelling manufacturers to either substantiate their products with robust data or face market exclusion. For global investors and business professionals focused on Chinese equities, this regulatory shift presents both risks and opportunities, as it redefines market dynamics, compels industry consolidation, and underscores a broader push toward transparency and quality in China’s healthcare landscape.
The Regulatory Deadline: A “Life-and-Death Clause” for TCM
Announced by the National Medical Products Administration (NMPA, 国家药品监督管理局), the new rule stipulates that from July 1, 2026, TCM products with labels still indicating “尚不明确” for adverse reactions, contraindications, or precautions will not be granted re-registration. This effectively bans their sale, triggering a sweeping TCM product elimination that targets long-standing practices in the industry. The regulation is part of a broader effort to modernize TCM by enforcing standards comparable to those for Western pharmaceuticals, ensuring that products are backed by empirical safety data.
What the New Rule Entails
The requirement extends beyond mere label changes; it mandates that TCM product holders conduct comprehensive post-market safety studies, including toxicology tests, real-world research, and pharmacovigilance database development. This closes a loophole that allowed products like Lianhua Qingwen (连花清瘟), Huoxiang Zhengqi Shui (藿香正气水), and Liuwei Dihuang Wan (六味地黄丸) to thrive for years without clear safety disclosures. The NMPA’s directive emphasizes that “尚不明确” is no longer acceptable, forcing a reckoning for an industry accustomed to minimal regulatory scrutiny.
Historical Context and the Urgency for Change
The tolerance for ambiguous labels dates back to 2006, when the China Food and Drug Administration (CFDA, 国家食品药品监督管理局) issued guidelines acknowledging the特殊性 (special characteristics) of TCM. Over time, however, this led to systemic abuse, with manufacturers using vague labels as a de facto shield against liability. Professor Sun Zhongshi (孙忠实), a former expert at the NMPA’s drug evaluation center, recalled the challenges: “We were very头疼 (headached) reviewing these TCM products. Out of 18 items in the说明书 (label), about seven or eight were unclear.” This historical leniency has culminated in the current crackdown, driven by rising concerns over patient safety and international pressure for standardized healthcare regulations.
The Stark Reality: Data Reveals Widespread Labeling Gaps
The scale of this impending TCM product elimination is underscored by alarming statistics. Research from the China Food and Drug Regulation Magazine indicates that in the 2018 edition of the National Essential Drugs Directory, among 465 labels for 268 TCM varieties, only 20.64% listed adverse reactions, 30.1% specified contraindications, and a mere 1.07% detailed drug interactions. This data highlights how the majority of products have relied on模糊表述 (ambiguous statements) to remain commercially viable, posing significant risks to consumers.
Quantifying the Risk: Over 70% of Approvals at Stake
With more than 70% of TCM product approvals—amounting to tens of thousands from a total of approximately 57,000—exhibiting labeling deficiencies, the industry faces a monumental challenge. Many of these are “僵尸批文” (zombie approvals) for products that are rarely produced or have negligible clinical value. Their elimination is expected to have minimal impact on the supply of commonly used品种 (varieties), but it will cleanse the market of low-quality offerings, reinforcing the TCM product elimination as a quality-over-quantity initiative.
Case Studies: From He Shou Wu to Common Formulas
Examples like He Shou Wu (何首乌) products illustrate the urgency. Despite known risks of liver damage, some “Jing Wu Pian” (精乌片) or “Shou Wu Wan” (首乌丸) labels still state “不良反应尚不明确” (adverse reactions not yet clear) while claiming to “补肝肾” (tonify liver and kidney). The NMPA has issued warnings about such discrepancies, prompting this regulatory overhaul. This TCM product elimination aims to eradicate such contradictions, ensuring that labels accurately reflect safety profiles.
Cost of Compliance: Who Bears the Brunt?
The financial implications of this TCM product elimination are staggering, particularly for small and medium enterprises (SMEs). According to a report by 21st Century Business Herald, for a traditional TCM product with annual sales of 20 million yuan,补齐安全数据 (completing safety data) requires at least three years and an investment of 20 million yuan, covering毒理试验 (toxicology tests), real-world studies, and pharmacovigilance infrastructure. This cost could obliterate profits for many smaller manufacturers, forcing them out of the market.
Financial Burden on SMEs and Market Exit
For SMEs, the compliance burden is prohibitive. An industry analyst noted that “中腰部企业 (mid-tier firms) two years may lose half their批文 (approvals), while尾部小企业 (tail-end small enterprises) face全面出清 (complete clearance).” This disparity underscores how the TCM product elimination will exacerbate inequalities, with resource-poor firms struggling to survive. In contrast, large pharmaceutical companies with ample capital and research capabilities are better positioned to adapt, investing in safety studies without crippling their operations.
Survival of the Fittest: Winners and Losers
The analyst further predicted that头部企业 (leading enterprises) could retain over 70% of core products, benefiting from reduced competition as weaker players exit. Firms with独家品种 (exclusive varieties) or特色原料供应能力 (unique raw material supply capabilities) may also weather the storm. This consolidation phase of the TCM product elimination will likely reshape the competitive landscape, favoring entities that prioritize innovation and compliance.
Expert Voices: Balancing Tradition and Modern Science
This regulatory shift is not about否定中药 (negating TCM) but拯救中药 (saving it), as emphasized by thought leaders. Renowned biologist Professor Rao Yi (饶毅) articulated the core principle: “Whether it’s Chinese or Western medicine, two core points remain unchanged: therapeutic effect and acceptable side effects. Any medical method must pass these tests.” His perspective highlights that the TCM product elimination is a necessary step to align tradition with modern evidence-based standards, ensuring that TCM remains credible and effective in a global context.
Insights from Regulatory Experts
Professor Sun Zhongshi’s recollections of regulatory headaches underscore the historical inertia that led to this point. Meanwhile, current experts, such as those cited in State Council documents, agree that 30-40% of TCM approvals will exit the market within 3-5 years. This consensus validates the TCM product elimination as a transformative force, pushing the industry from “数量扩张” (quantity expansion) to “质量优先” (quality first).
Long-term Implications for TCM Quality and Global Perception
By enforcing stricter labeling, China aims to enhance the global reputation of TCM, making it more palatable to international markets wary of unsubstantiated health claims. This TCM product elimination could spur innovation, as companies invest in research to differentiate their products, ultimately fostering a more robust and trustworthy sector.
Market Transformation: Winners, Losers, and Investment Insights
The TCM product elimination marks the end of the “只进不出” (only in, no out) approval红利时代 (benefit era), where approvals were rarely revoked. Moving forward, investors must recalibrate their strategies to account for this seismic shift. Large, publicly listed firms like Yunnan Baiyao (云南白药) or Beijing Tongrentang (北京同仁堂) may see stock appreciation as they capitalize on market consolidation, while SMEs and those holding “zombie approvals” face significant devaluation risks.
Investment Opportunities in a Consolidating Market
Investors should focus on companies with strong R&D pipelines, proactive label revisions, and robust financials. The TCM product elimination creates opportunities in equities that demonstrate compliance readiness and potential for market share growth. Monitoring regulatory filings and clinical trial updates will be crucial for identifying winners in this evolving landscape.
Risks and Mitigation Strategies
Key risks include regulatory non-compliance, liquidity crunches for SMEs, and potential supply chain disruptions. Diversifying portfolios away from firms reliant on ambiguous labels and toward those with clear safety data can mitigate exposure. Engaging with industry reports, such as those from the NMPA or financial analysts, will provide timely insights into this TCM product elimination process.
Looking Ahead: Policy Support and Future Trends
The State Council’s February 2023 opinion on promoting high-quality development of the TCM industry outlines a roadmap that includes guiding manufacturers to改良一批 (improve a batch) and依法淘汰一批 (eliminate a batch according to law). This structured approach ensures that the TCM product elimination is managed systematically, minimizing market shocks while advancing public health goals.
Government Initiatives and Regulatory Guidance
Authorities are likely to offer support through streamlined approval processes for updated labels and incentives for innovation. Investors should track policy announcements from the NMPA and related bodies to anticipate further regulatory adjustments. This TCM product elimination is part of a broader trend toward harmonizing China’s pharmaceutical standards with global benchmarks, which could open doors for international collaborations and investments.
Call to Action for Stakeholders
For industry players, accelerating safety studies and revising labels is imperative. For investors, conducting due diligence on TCM companies’ compliance status and long-term strategies will be key to capitalizing on this transition. As the 2026 deadline approaches, staying informed through reliable sources and expert analyses will enable proactive decision-making in a market reshaped by this historic TCM product elimination.
The TCM product elimination driven by China’s new regulations is a pivotal development with far-reaching consequences for the pharmaceutical sector and investment community. By mandating transparency and safety, regulators are not only protecting consumers but also steering the industry toward sustainable growth. For savvy investors, this represents a chance to engage with a maturing market where quality and innovation are paramount. As the landscape evolves, continuous monitoring of regulatory compliance, company performance, and market trends will be essential to navigating the opportunities and risks presented by this transformative period in Chinese equities.